Tumor Mutational Burden and Response Rate to PD-1 Inhibition
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
In a survey of the spectrum of mutational burdens in 27 types of cancers, there was a correlation between an increased mutational burden and the response to checkpoint inhibition of PD-1 and PD-L1.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, these studies are limited to particular cancer types and subsets of patients, due to difference in mutation load seen in different cancer types, and immune-related adverse effects of therapy may occur [93][94][95][96].”
From Cancer-on-chip models for metastasis: importance of the tumor microenvironment (2024) · cites this paper as [93]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“While these markers have clinical utility in specific contexts, their predictive accuracy varies considerably across tumor histologies and patient populations.”
From PathTIGR: A pathway topology-informed graph representation learning framework for immunotherapy response prediction (2026) · doi:10.1126/sciadv.aed6373 · cites this paper as [13]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“While high TMB and immune checkpoint molecule expression, including PD-L1, have been used as predictive biomarkers across different cancer types, they have limited clinical utility when considered in isolation88,101.”
From Multi-omic analysis of hepatocellular carcinoma reveals aberrant cis-regulatory changes and dysregulated retrotransposons with prognostic potential (2025) · cites this paper as [88]
Experimental — accuracy not yet measuredIn the citing paper
“Although high TMB led to FDA approval, it should be noted that certain tumor types with moderate TMB carry relatively high response rates to ICT, such as clear cell RCC (128, 129).”
From The Next Decade of Immune Checkpoint Therapy (2021) · cites this paper as [128]
In the citing paper
“Melanoma, lung, and bladder cancer, tumors commonly associated with an increased number of mutations due to environmental DNA damage, exhibit a stronger response to ICB (Yarchoan et al., 2017).”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as Yarchoan et al., 2017
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645
Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden
Chalmers, Z. R., Connelly, C. F., Fabrizio, D., Gay, L., Ali, S. M., Ennis, R., Schrock, A., Campbell, B., Shlien, A., Chmielecki, J., et al. (2017) · Genome Medicine · doi:10.1186/s13073-017-0424-2 · Cited by 3,519
PD-1 Blockade with pembrolizumab in advanced Merkel-cell carcinoma
Nghiem, P. T., Bhatia, S., Lipson, E. J., Kudchadkar, R. R., Miller, N. J., Annamalai, L., Berry, S., Chartash, E. K., Daud, A., Fling, S. P., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603702 · Cited by 1,258
Cited by
Items 901–1,000 of 1,006
Qi, X. (2022) · American Journal of Cancer Research · doi:10.62347/etjh6697 · Cited by 34
Daly, R. J., Scott, A. M., Klein, O., & Ernst, M. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01656-z · Cited by 40
“By contrast, tumors with high tumor mutational burden (TMB) and which arise in an immune permissive TME present with a higher immune activation potential and are therefore more likely to respond to single agent ICI therapies [7].”
BackgroundWang, X., Zha, H., Wu, W., Yuan, T., Xie, S., Jin, Z., Long, H., Yang, F., Wang, Z., Zhang, A., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.abn5029 · Cited by 36
“To include more type of tumors, we applied our analysis based on our CD200+PD-1+CD8+ T cell feature gene set to include data for patients with invasive breast carcinoma, pancreatic adenocarcinoma, glioblastoma multiforme, esophageal carcinoma, prostate adenocarcinoma, stomach adenocarcinoma, ovarian serous cystadenoca…”
MethodSystemic Therapy for Advanced Hepatocellular Carcinoma: Current Stand and Perspectives
Girardi, D. M., Sousa, L. P., Miranda, T. A., Haum, F. N. C., Pereira, G. C. D. B., & Pereira, A. A. L. (2023) · Cancers · doi:10.3390/cancers15061680 · Cited by 39
“The tumor mutational burden (TMB) is defined as the total number of mutations per coding area of a tumor genome and is a biomarker of response to anti-PD-1 therapy [84,85].”
BackgroundJi, J. H., Ha, S. Y., Lee, D., Sankar, K. N., Koltsova, E. K., Abou‐Alfa, G. K., & Yang, J. D. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24087640 · Cited by 40
“There is a wealth of data that demonstrated that TMB is associated with immunotherapy response, with TMB having predictive value as a biomarker in most cancer subtypes [56].”
BackgroundStouten, I., van Montfoort, N., & Hawinkels, L. J. A. C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24108707 · Cited by 38
“The low mutational burden in PDAC is one of the potential explanations underlying the low response rates [8].”
BackgroundImplementing precision cancer medicine in the genomic era
Chen, H., Bonneville, R., & Roychowdhury, S. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2018.05.009 · Cited by 38
Pedro, B. A., & Wood, L. D. (2025) · Journal of Clinical Investigation · doi:10.1172/jci191937 · Cited by 36
“…is known to possess a relatively low tumor mutational burden that seems to limit its responsiveness to immune checkpoint inhibitor (ICI) therapy (120), recent evidence showing increased immune checkpoint marker expression in HG-IPMNs (68) suggests a possible role for ICIs in targeting precursor…”
Criticality in tumor evolution and clinical outcome
Persi, E., Wolf, Y. I., Leiserson, M. D. M., Koonin, E. V., & Ruppin, E. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1807256115 · Cited by 40
“Further, both high ML (50) and high microsatellite instability (51) evoke immune response, due to the generation of neo-antigens, such that, in addition to intracellular mechanisms, negative selection could be exercised by the immune system (52).”
Hatakeyama, K., Nagashima, T., Ohshima, K., Ohnami, S., Ohnami, S., Shimoda, Y., Serizawa, M., Maruyama, K., Naruoka, A., Akiyama, Y., et al. (2019) · Cancer Science · doi:10.1111/cas.14087 · Cited by 34
Wu, X., Lan, X.-L., Hu, W., Zhang, W., Lai, X., Xu, S., Li, J., Qiu, W., Wang, W., Xiao, J., et al. (2021) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-021-02931-6 · Cited by 37
“Although PD-L1 expression, tumor mutational burden (TMB) and tumor-infiltrating lymphocyte density have been reported to predict the efficacy of immune checkpoint inhibitor antibodies in CRC, the predictive value of these biomarkers remains controversial [14, 15].”
BackgroundTumor Microenvironment in Adrenocortical Carcinoma: Barrier to Immunotherapy Success?
Georgantzoglou, N., Kokkali, S., Tsourouflis, G. S., & Theocharis, S. E. (2021) · Cancers · doi:10.3390/cancers13081798 · Cited by 34
“TMB is a promising emerging biomarker in patient selection for immune checkpoint inhibitor therapy, as an increasing level of evidence suggests that higher TMB is associated with increased responsiveness to immunotherapy [86].”
BackgroundComprehensive molecular profiling of pulmonary pleomorphic carcinoma
Nagano, M., Kohsaka, S., Hayashi, T., Ueno, T., Kojima, S., Shinozaki‐Ushiku, A., Morita, S., Tsuda, M., Tanaka, S., Shinohara, T., et al. (2021) · npj Precision Oncology · doi:10.1038/s41698-021-00201-3 · Cited by 36
Hsu, S., Jadhao, M., Liao, W., Chang, W., Hung, C.-T., & Chiu, C. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.1020888 · Cited by 37
“The poor response to ICIs is primarily attributed to a low tumour mutation burden, an immunosuppressive TME and physical barriers (Yarchoan et al., 2017; Hester et al., 2021).”
BackgroundAdashek, J. J., Kato, S., Nishizaki, D., Miyashita, H., De, P. K., Lee, S., Pabla, S., Nesline, M., Conroy, J. M., DePietro, P., et al. (2023) · Cancer Medicine · doi:10.1002/cam4.6000 · Cited by 34
Immunotherapy in Head and Neck Cancer: Where Do We Stand?
Vallianou, N. G., Evangelopoulos, A. A., Kounatidis, D. C., Panagopoulos, F., Geladari, E. V., Karampela, Ι., Stratigou, T., & Dalamaga, Μ. (2023) · Current Oncology Reports · doi:10.1007/s11912-023-01425-1 · Cited by 39
PPARγ inhibited tumor immune escape by inducing PD‐L1 autophagic degradation
Gou, Q., Che, S., Chen, M., Chen, H., Shi, J., & Hou, Y. (2023) · Cancer Science · doi:10.1111/cas.15818 · Cited by 34
James, J. L., Taylor, B. C., Axelrod, M. L., Sun, X., Guerin, L. N., Ericsson, P. I. G., Wang, Y., Sanchez, V. M., Fahey, C. C., Sanders, M. E., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-007736 · Cited by 34
Advances and challenges in the treatment of osteosarcoma
Wang, X., Zhu, K., Hu, J., & Zhang, C. (2025) · Progress in Biophysics and Molecular Biology · doi:10.1016/j.pbiomolbio.2025.07.001 · Cited by 38
Combined Flt3L and CD40 agonism restores dendritic cell–driven T cell immunity in pancreatic cancer
Hogg, G. D., Weinstein, A. G., Kingston, N. L., Liu, X., Dres, O. M., Kang, L., Lander, V. E., Kao, Y., Ahmad, F. F., Knolhoff, B. L., et al. (2025) · Science Immunology · doi:10.1126/sciimmunol.adp3978 · Cited by 34
Skrzypski, M. T., & Jassem, J. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.04.001 · Cited by 33
Smoragiewicz, M., Bogaerts, J., Calvo, E., Marabelle, A., Perrone, A., Seymour, L., Shalabi, A., Siu, L. L., Tabernero, J. M., Giaccone, G., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy398 · Cited by 33
Mistry, A. M., Greenplate, A. R., Ihrie, R. A., & Irish, J. M. (2019) · FEBS Journal · doi:10.1111/febs.14730 · Cited by 33
Somatic mutation of LRP1B is associated with tumor mutational burden in patients with lung cancer
Lan, S., Li, H., Liu, Y., Ma, L., Liu, X., Liu, Y., Yan, S., & Cheng, Y. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.04.025 · Cited by 37
Genetic Biomarkers in Melanoma of the Ocular Region: What the Medical Oncologist Should Know
Bol, K. F., Donia, M., Heegaard, S., Kiilgaard, J. F., & Svane, I. M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21155231 · Cited by 36
Halbert, B. T., & Einstein, D. J. (2020) · Urology · doi:10.1016/j.urology.2020.10.030 · Cited by 35
Liu, S., Tang, Q.-J., Huang, J., Zhan, M., Zhao, W., Yang, X., Li, Y., Qiu, L., Zhang, F., Lu, L., et al. (2021) · Aging · doi:10.18632/aging.202811 · Cited by 39
“TMB is a novel biomarker that is calculated as genetic variations per million bases of the encoded genome [23, 24].”
BackgroundImmunotherapy for Hepatocellular Carcinoma: Current Limits and Prospects
Zhong, C. F., Li, Y., Yang, J., Jin, S., Chen, G., Li, D., Fan, X., & Lin, H. M. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.589680 · Cited by 37
“Tumor Mutational Burden Immunotherapies are ineffective for HCC because of the low tumor mutational burden of HCC compared to that of melanoma or non‐small cell lung carcinoma (109).”
BackgroundMoreira, A., Poulet, A., Masliah‐Planchon, J., Lecerf, C., Vacher, S., Chérif, L. L., Dupain, C., Marret, G., Girard, E., Syx, L., et al. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100178 · Cited by 36
Lesion-level heterogeneity of radiologic progression in patients treated with pembrolizumab
Topp, B. G., Thiagarajan, K., de Alwis, D. P., Snyder, A., & Hellmann, M. D. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.09.006 · Cited by 33
Sturgill, E. G., Misch, A., Jones, C. C., Luckett, D. J., Fu, X., Schlauch, D., Jones, S. F., Burris, H. A., Spigel, D. R., & McKenzie, A. J. (2022) · The Oncologist · doi:10.1093/oncolo/oyab064 · Cited by 34
Ge, Y., Zhang, Y., Zhao, K., & Zhu, H. (2022) · Drug Design Development and Therapy · doi:10.2147/dddt.s374672 · Cited by 34
“high mutational burdens are theoretically highly responsive to PD-1/PD-L1 blockade therapy but practically show low levels of response because of these immunoevasive and immunosuppressive mechanisms.(28) Therefore, combining PD-1/PD-L1 blockade”
BackgroundChen, J., Liu, Z., Wu, Z., Li, W., & Tan, X. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1132424 · Cited by 41
“TMB is a proxy of tumor antigenicity, and high-TMB patients tend to respond favorably to immunotherapy (68).”
BackgroundImmunotherapy in Glioblastoma: A Clinical Perspective
Desbaillets, N., & Hottinger, A. F. (2021) · Cancers · doi:10.3390/cancers13153721 · Cited by 31
“In general, the tumor mutation load is associated with a better response to immune CPIs [82].”
BackgroundInfluentialFurukawa, N., Stearns, V., Santa-Maria, C. A., & Popel, A. S. (2022) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2022.2170779 · Cited by 37
“Breast cancer has been regarded as less immunogenic compared to other types of cancer due to relatively low infiltration of immune cells in the tissue [24] and low tumor mutational burden (TMB) [25].”
BackgroundYu, D., Yang, P., Lu, X., Huang, S., Liu, L., & Fan, X. (2023) · Cell Communication and Signaling · doi:10.1186/s12964-023-01184-3 · Cited by 34
“However, the overall objective response rate for PD-1 and PD-L1 inhibitors in NSCLC is unsatisfactory (less than 20%) [6], and PD-1 resistance may appear in patients with advanced NSCLC [7].”
BackgroundXia, H., Zhang, W., Zheng, Q., Zhang, Y., Mu, X. N., Wei, C., Wang, X., & Liu, Y. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e17400 · Cited by 36
Shaping immune landscape of colorectal cancer by cholesterol metabolites
Bai, Y., Li, T., Wang, Q., You, W., Yang, H., Xu, X., Li, Z., Zhang, Y., Yan, C., Yang, L., et al. (2024) · EMBO Molecular Medicine · doi:10.1038/s44321-023-00015-9 · Cited by 35
Unraveling molecular aberrations and pioneering therapeutic strategies in osteosarcoma
Yan, P., Wang, J., Yue, B., & Wang, X. (2024) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2024.189171 · Cited by 32
Davar, D., Carneiro, B. A., Dy, G. K., Sheth, S. H., Borad, M. J., Harrington, K. J., Patel, S. P., Galanis, E., Samson, A., Agrawal, S., et al. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-009336 · Cited by 36
Califano, R., Lal, R., Lewanski, C. R., Nicolson, M. C., Ottensmeier, C. H. H., Popat, S., Hodgson, M. J., & Postmus, P. E. (2018) · Future Oncology · doi:10.2217/fon-2018-0330 · Cited by 37
Predictive biomarkers of response to immune checkpoint inhibitors in melanoma
Nebhan, C. A., & Johnson, D. B. (2020) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2020.1724539 · Cited by 32
“The evidence of this hypothesis is as follows: In general, tumors with higher TMB are also, in general, the ones which respond to checkpoint inhibitors [20].”
BackgroundBilateral murine tumor models for characterizing the response to immune checkpoint blockade
Zemek, R. M., Fear, V. S., Forbes, C., de Jong, E., Casey, T. H., Boon, L., Lassmann, T., Bosco, A., Millward, M., Nowak, A. K., et al. (2020) · Nature Protocols · doi:10.1038/s41596-020-0299-3 · Cited by 34
Potential of Pembrolizumab in Metastatic or Recurrent Head and Neck Cancer: Evidence to Date
McCusker, M. G., Orkoulas-Razis, D., & Mehra, R. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s196252 · Cited by 33
Zhao, Z., Zhang, N., Li, A., Zhou, B., Chen, Y., Chen, S., Huang, M., Wu, F., & Zhang, L. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.04.013 · Cited by 33
Granzyme B PET Imaging of Immune Checkpoint Inhibitor Combinations in Colon Cancer Phenotypes
Goggi, J., Tan, Y. X., Hartimath, S. V., Jieu, B., Hwang, Y. Y., Jiang, L., Boominathan, R., Cheng, P. K. C., Yuen, T. Y., Chin, H. X., et al. (2020) · Molecular Imaging and Biology · doi:10.1007/s11307-020-01519-3 · Cited by 31
Cassaday, R. D., Garcia, K. A., Fromm, J. R., Percival, M. M., Turtle, C. J., Nghiem, P., Stevenson, P. A., & Estey, E. H. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020002403 · Cited by 34
“As for other possible explanations for inefficacy of pembrolizumab, tumor mutational burden has been correlated with response to anti–PD-1 antibodies.(22) Even with its relatively low mutational rate, an analysis of somatic mutations in pediatric ALL predicted immunogenicity in vitro, suggesting such an approach could…”
BackgroundCho, R., Sakurai, Y., Jones, H. S., Akita, H., Hisaka, A., & Hatakeyama, H. (2020) · Cancers · doi:10.3390/cancers12123630 · Cited by 31
“The objective response rate (ORR) to aPD-1 mAbs such as nivolumab and pembrolizumab has been reported to be limited to around 20% [2].”
BackgroundImmunotherapies in clinical development for biliary tract cancer
Vogel, A., Bathon, M., & Saborowski, A. L. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2021.1868437 · Cited by 31
“In line with the observation that highly mutated tumors can produce many tumor-specific neoantigens, some of which can be recognized by the immune system, high TMB has been shown to correlate with clinical benefit of antibodies targeted against CTLA-4, PD-1, and PD-L1 in multiple tumors including melanoma and NSCLC [5…”
BackgroundDrug and molecular radiotherapy combinations for metastatic castration resistant prostate cancer
Staniszewska, M., Iking, J., Lückerath, K., Hadaschik, B. A., Herrmann, K., Ferdinandus, J., & Fendler, W. P. (2021) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2021.03.009 · Cited by 33
KMT2C is a potential biomarker of prognosis and chemotherapy sensitivity in breast cancer
Liu, X., Qiu, R., Xu, M., Meng, M., Zhao, S., Ji, J., & Yang, Y. (2021) · Breast Cancer Research and Treatment · doi:10.1007/s10549-021-06325-1 · Cited by 38
Xie, X., Tang, Y., Sheng, J., Shu, P., Zhu, X., Cai, X., Zhao, C., Wang, L., & Huang, X. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.761758 · Cited by 32
“Tumor mutation burden, referring to the overall mutation volume per coding area in the cancer genome, is high in cancer specimens and has become an underlying marker in tumor immune treatment (Goodman et al., 2017; Yarchoan et al., 2017).”
BackgroundInfluence of Helicobacter pylori infection on PD‐1/PD‐L1 blockade therapy needs more attention
Shi, Y., Zheng, H., Wang, M., & Ding, S. (2022) · Helicobacter · doi:10.1111/hel.12878 · Cited by 35
Zhang, Z., Zheng, M., Ding, Q., & Liu, M. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.817965 · Cited by 35
“Given that TMB status is gradually regarded as one of the promising pan-cancer biomarkers for forecasting ICB therapeutic effect, which has already been approved by the FDA (Chan et al., 2019), we checked the correlation between CD93 expression and TMB across cancers.”
BackgroundInfluentialRecurrent somatic mutations as predictors of immunotherapy response
Gajic, Z. Z., Deshpande, A. S., Legut, M., Imielinski, M. B., & Sanjana, N. E. (2022) · Nature Communications · doi:10.1038/s41467-022-31055-3 · Cited by 35
Shi, C., Wang, Y., Xue, J., & Zhou, X. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.940288 · Cited by 43
Biomarkers for response to immunotherapy in hepatobiliary malignancies
Lin, Z., Qin, L., & Chen, J. (2022) · Hepatobiliary & pancreatic diseases international · doi:10.1016/j.hbpd.2022.08.002 · Cited by 32
Harnessing the immune system by targeting immune checkpoints: Providing new hope for Oncotherapy
Yu, L., Sun, M., Zhang, Q., Zhou, Q., & Wang, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.982026 · Cited by 33
van den Bulk, J., van der Ploeg, M., Ijsselsteijn, M. E., Ruano, D., van der Breggen, R., Duhen, R., Peeters, K. C. M. J., Sarasqueta, A. F., Verdegaal, E. M. E., van der Burg, S. H., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005887 · Cited by 34
Smart drug delivery systems to overcome drug resistance in cancer immunotherapy
Yi, W., Yan, D., Wang, D., & Li, Y. (2023) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2023.0009 · Cited by 32
Li, L., Rao, X., Wen, Z., Ding, X., Wang, X., Xu, W., Meng, C., Yi, Y., Guan, Y., Chen, Y., et al. (2020) · Oncology Letters · doi:10.3892/ol.2020.11372 · Cited by 36
“Advances in next‐generation sequencing (NGS) has iden‐ tified tumor mutation burden (TMB) as a potential biomarker for predicting the response of patients with multiple tumors to ICB therapy (9,10).”
BackgroundNaganuma, A., Sakuda, T., Murakami, T., Aihara, K., Watanuki, Y., Suzuki, Y., Shibasaki, E., Masuda, T., Uehara, S., Yasuoka, H., et al. (2020) · Internal Medicine · doi:10.2169/internalmedicine.4588-20 · Cited by 32
“Of interest, the enhancement of antitumor effects of ICIs through the concomitant use of local RT has been reported for various advanced cancers, including melanoma (22, 23).”
BackgroundInfluentialThe relationship between autophagy and PD-L1 and their role in antitumor therapy
Cui, Y., Shi, J., Cui, Y., Zhu, Z., & Zhu, W. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1093558 · Cited by 36
“the clinical efficacy of drugs targeting PD1/PD-1 alone is poor (44), and even fulminant tumor progression occurs.”
BackgroundRefining PD-1/PD-L1 assessment for biomarker-guided immunotherapy: A review
Zdrenka, M., Kowalewski, A., Ahmadi, N., Sadiqi, R. U., Chmura, Ł., Borowczak, J., Maniewski, M., & Szylberg, Ł. (2024) · Biomolecules and Biomedicine · doi:10.17305/bb.2023.9265 · Cited by 35
“In a recent meta-analysis, the objective response rate (ORR) to PD-1/PD-L1 therapy increased with TMB in 27 cancers [93].”
BackgroundFriedman, C. F., Manning‐Geist, B. L., Zhou, Q. C., Soumerai, T. E., Holland, A., Paula, A. D. C., Green, H., Ozsoy, M. A., Iasonos, A. E., Hollmann, T. J., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-02942-7 · Cited by 36
“TMB was used in several studies as a biomarker for response to immunotherapy 34,35 , and pembrolizumab now has an FDA-approved indication for advanced solid tumors with a TMB of ≥10 mutations per megabase (mut/Mb) as measured by the FoundationOne CDx assay.”
Evaluating [225Ac]Ac-FAPI-46 for the treatment of soft-tissue sarcoma in mice
Taddio, M. F., Doshi, S., Masri, M., Jeanjean, P., Hikmat, F., Gerlach, A., Nyiranshuti, L., Rosser, E. W., Schaue, D., Besserer‐Offroy, É., et al. (2024) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-024-06809-4 · Cited by 30
“To imitate the clinically lower responsiveness of sarcoma to anti-PD1 [ 29, 30], we induced local immunosuppression by co-inoculation of tumor cells with Abatacept.”
BackgroundImmunotherapy in colorectal cancer
Agarwal, P., Le, D. T., & Boland, P. M. (2021) · Advances in cancer research · doi:10.1016/bs.acr.2021.03.002 · Cited by 35
Therapeutic management of neuro-oncologic patients - potential relevance of CSF liquid biopsy
von Baumgarten, L., Kumbrink, J., Jung, A., Reischer, A., Flach, M., Liebmann, S., Metzeler, K. H., Holch, J. W., Niyazi, M., Thon, N., et al. (2019) · Theranostics · doi:10.7150/thno.36884 · Cited by 31
“checkpoint inhibitors in several tumor types [27, 32].”
ResultXia, R., Xiao, J., Zhang, Y., Teng, H., Cheng, F., Chen, H., Zhang, K., & Sun, Z. (2020) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835920977117 · Cited by 36
Girardi, D. M., Pacifico, J. P. M., de Amorim, F. P. L. G., Fernandes, G. D. S., Teixeira, M. C., & Pereira, A. A. L. (2020) · Pharmaceuticals · doi:10.3390/ph14010028 · Cited by 31
“Unfortunately, HCC has a low median TMB (5 Mut/Mb) [70].”
BackgroundLiu, C., Zhou, F., Yan, Z., Shen, L., Zhang, X., He, F., Wang, H., Lu, X., Yu, K., Zhao, Y., et al. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15457 · Cited by 32
“Tumour mutational burden is one of the most widely used immunotherapy biomarkers to identify the patient response and predict therapeutic efficacy (Yarchoan et al., 2017).”
BackgroundComprehensive tumor molecular profile analysis in clinical practice
Özdoğan, M., Papadopoulou, E., Τσούλος, Ν., Tsantikidi, A., Mariatou, V.-M., Tsaousis, G., Kapeni, E., Bourkoula, E., Fotiou, D. F., Kapetsis, G., et al. (2021) · BMC Medical Genomics · doi:10.1186/s12920-021-00952-9 · Cited by 31
“TMB has emerged as a promising biomarker of response to such treatments, and several clinical trials have shown that both blood and tissue samples TMB can effectively be used [23, 25, 27, 81].”
Cai, Y., Wang, X., Wang, N., Wu, J., Ma, L., Xie, X., Zhang, H., Dang, C., Kang, H., Zhang, S., et al. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119505 · Cited by 39
Cao, C., Liu, R., Lin, X., Luo, J., Cao, L., Zhang, Q., Lin, S., Geng, L., Sun, Z., Ye, S.-K., et al. (2021) · International Journal of Biological Sciences · doi:10.7150/ijbs.56970 · Cited by 34
“Higher tumor mutational burden shows distinct clinicopathologic features and is a biomarker for good efficacy and clinical response to ICIs in diverse cancers [38].”
BackgroundItoh, T., Kawai, Y., Yasui, Y., Iriguchi, S., Minagawa, A., Ishii, T., Miyoshi, H., Taketo, M. M., Kawada, K., Obama, K., et al. (2021) · Communications Biology · doi:10.1038/s42003-021-02195-x · Cited by 32
Targeted therapies: Expanding the role of FGFR3 inhibition in urothelial carcinoma
Zengin, Z. B., Chehrazi‐Raffle, A., Salgia, N., Muddasani, R., Ali, S., Meza, L., & Pal, S. K. (2021) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2021.10.003 · Cited by 32
Immunogenomic Landscape in Breast Cancer Reveals Immunotherapeutically Relevant Gene Signatures
Wang, T., Li, T., Li, B., Zhao, J., Li, Z., Sun, M., Li, Y., Zhao, Y., Zhao, S., He, W., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.805184 · Cited by 39
“Except for the fact that breast cancer exhibits similar immunologically silent properties, a low mutational burden, and fewer tumor-infiltrating lymphocytes (TILs) than some other cancers (12, 13), the lack of an immunogenomic approach for appropriate patient selection and precise prognostic biomarkers might be the ma…”
BackgroundTargeting the tumor mutanome for personalized vaccination in a TMB low non-small cell lung cancer
McCann, K. J., Witzleben, A. V., Thomas, J., Wang, C., Wood, O., Singh, D. K., Boukas, K., Bendjama, K., Silvestre, N., Nielsen, F. C., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003821 · Cited by 36
Kim, H., Choi, J., & Lee, K. (2022) · Biomedicines · doi:10.3390/biomedicines10051130 · Cited by 30
“Meta-analysis of 27 types of tumors revealed that high mutational burden was correlated with improved ORR in patients who received anti-PD-1/PD-L1 therapy [45].”
BackgroundWen, X., Zeng, X., Cheng, X., Zeng, X., Liu, J., Zhang, Y., Li, Y., Chen, H., Huang, J., Guo, Z., et al. (2022) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.2c00281 · Cited by 30
The role of viruses in HIV-associated lymphomas
Lurain, K. A., Ramaswami, R., & Yarchoan, R. (2022) · Seminars in Hematology · doi:10.1053/j.seminhematol.2022.11.002 · Cited by 32
Blocking CD47-SIRPα Signal Axis as Promising Immunotherapy in Ovarian Cancer
Luo, X., Shen, Y., Huang, W., Bao, Y., Mo, J., Yao, L., & Yuan, L. (2023) · Cancer Control · doi:10.1177/10732748231159706 · Cited by 32
Chatani, P. D., Lowery, F. J., Parikh, N. B., Hitscherich, K. J., Yossef, R., Hill, V. K., Gartner, J. J., Paria, B. C., Florentin, M., Ray, S., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-006264 · Cited by 34
Yu, J., Li, M., Ren, B., Cheng, L., Wang, X., Ma, Z., Yong, W. P., Chen, X., Wang, L., & Goh, B. C. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1261575 · Cited by 34
“A crossover study involving multiple cancer types demonstrated that tumors with higher TMB exhibited better responses to PD-1/PD-L1 therapy, and there was a positive correlation between TMB and PD-L1 expression on tumor cells (Yarchoan et al., 2017).”
BackgroundLi, Y., Mahadevan, N. R., Duplaquet, L., Hong, D., Durmaz, Y. T., Jones, K. L., Cho, H., Morrow, M., Protti, A., Poitras, M. J., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101282 · Cited by 36
PRAME Expression: A Target for Cancer Immunotherapy and a Prognostic Factor in Uveal Melanoma
Gelmi, M. C., Gezgin, G., van der Velden, P. A., Luyten, G. P. M., Luk, S. J., Heemskerk, M. H. M., & Jager, M. J. (2023) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.64.15.36 · Cited by 30
“53,54 Moreover, PD-L1 expression in UM has been reported to occur only in 10% of the primary tumors and 5% of UM metastases.”
Identification of Novel HLA Class II-Restricted Neoantigens Derived from Driver Mutations
Iiizumi, S., Ohtake, J., Murakami, N., Kouro, T., Kawahara, M., Isoda, F., Hamana, H., Kishi, H., Nakamura, N., & Sasada, T. (2019) · Cancers · doi:10.3390/cancers11020266 · Cited by 33
“Considerable attention has recently been paid to T cell responses to neoantigens derived from tumor-specific genetic mutations, sinc umors with many mut ti ns h ve been demonstrated to be more likely to respo d to immune ch ckpoint inhibitors than tumors with fewer mutations in can er patients [7].”
BackgroundCardona, A. F., Rojas, L., Zatarain-Barrón, Z. L., Ruíz-Patiño, A., Ricaurte, L., Corrales, L., Martin, C. M., Freitas, H., de Lima, V. C. C., Rodríguez, J. K., et al. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00254 · Cited by 33
“TMB, a quantification of mutations in the tumor genome has been strongly associated with the response to immunotherapy with checkpoint inhibitors such as pembrolizumab or ipilimumab/nivolumab (34, 35).”
BackgroundKlein, S., Mauch, C., Wagener‐Ryczek, S., Schoemmel, M., Buettner, R., Quaas, A., & Helbig, D. (2019) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-019-02339-3 · Cited by 30
DiGuardo, M. A., Davila, J. I., Jackson, R. A., Nair, A., Fadra, N., Minn, K. T., Atiq, M. A., Zarei, S., Blommel, J. H., Knight, S. M., et al. (2021) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2021.01.008 · Cited by 32
Yang, C. G., Austin, F., Richard, H., Idowu, M. O., Williamson, V. S., Sabato, F., Ferreira‐Gonzalez, A., & Turner, S. A. (2019) · Molecular Case Studies · doi:10.1101/mcs.a003863 · Cited by 30
“Higher TMB and mismatch repair deficiencies lead to increased numbers of neoantigens and are now recognized as biomarkers for anti-PD-1/PD-L1 efficacy (Snyder et al. 2014; Le et al. 2015, 2017; Rizvi et al. 2015; Yarchoan et al. 2017; Hellmann et al. 2018).”
BackgroundTumor mutational burden and immune signatures interplay in renal cell carcinoma
Yakirevich, E., & Patel, N. R. (2020) · Annals of Translational Medicine · doi:10.21037/atm.2020.02.81 · Cited by 32
“However, more recent analysis has failed to confirm a higher frequency of indels in a larger randomized cohort of advanced metastatic RCC treated with ICPIs (7).”
BackgroundInfluentialYoshimoto, S., Chester, N., Xiong, A., Radaelli, E., Wang, H., Brillantes, M., Gulendran, G., Glassman, P. M., Siegel, D. L., & Mason, N. J. (2023) · mAbs · doi:10.1080/19420862.2023.2287250 · Cited by 29
“27 This is exemplified by the identification of positive responses to anti-PD-1 therapy in human patients with colorectal cancer with high microsatellite instability and/or mismatch repair deficiency (MSI-H/MMRd) compared to those with colorectal cancer that have low MSI and proficient MMR…”
BackgroundWheless, M. C., Agarwal, R., Goff, L. W., Lockney, N. A., Padmanabhan, C., & Heumann, T. R. (2024) · Current Treatment Options in Oncology · doi:10.1007/s11864-023-01153-5 · Cited by 38
“Similarly, a linear correlation has been observed in a wide range of solid tumors between TMB and response to ICI such that as TMB increases, response to ICI increases [130].”
BackgroundTumour-infiltrating lymphocyte therapy landscape: prospects and challenges
Chen, R., Johnson, J. E., Roudkoli, A. R., & Dudek, A. Z. (2025) · BMJ Oncology · doi:10.1136/bmjonc-2024-000566 · Cited by 36
“29 30 Within the TIL population, neoantigen-reactive T cells represent the most potent effectors of tumour clearance, as they can specifically recognise and eliminate cancer cells while sparing normal tissues.”
Li, L., Ye, Q., Ma, J., Wang, Z., Liu, T., Lei, Y., Lu, M., Kang, J., Xiang, H., Li, B., et al. (2026) · Cancer Cell · doi:10.1016/j.ccell.2025.12.013 · Cited by 33
Emerging biomarkers and targeted therapies in urothelial carcinoma
Mendiratta, P., & Grivas, P. D. (2018) · Annals of Translational Medicine · doi:10.21037/atm.2018.05.49 · Cited by 30
The Role of Anti-PD-1/PD-L1 in the Treatment of Skin Cancer
Patrinely, J. R., Dewan, A. K., & Johnson, D. B. (2020) · BioDrugs · doi:10.1007/s40259-020-00428-9 · Cited by 31
Saxena, M., Marron, T. U., Kodysh, J., Finnigan, J. P., Onkar, S., Kaminska, A., Tuballes, K., Guo, R., Sabado, R. L., Meseck, M., et al. (2025) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-0934 · Cited by 28
Shi, Y.-Y., Fan, G., Tan, R., Li, S., Sun, H.-B., Li, R., Yang, M., Gao, S., Liu, M., & Dai, M.-Y. (2024) · Cell Death & Disease · doi:10.1038/s41419-024-07073-y · Cited by 28
“Despite clinical success, variability in patient response and development of resistance pose signi fi cant challenges that are potentially linked to the tumor microenvironment, mutation burden, PD-L1 expression, and individual immune status [7 – 10].”
Metadata
- Authors
- Yarchoan, M., Hopkins, A., & Jaffee, E. M.
- Affiliations
- Johns Hopkins University (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2017-12-21
- Volume
- 377
- Issue
- 25
- Pages
- 2500-2501
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC6549688
- OpenAlex
- W2779221466
- Cited by
- 3,230
- References
- 5
- Citations by year
- 2026: 181 · 2025: 274 · 2024: 410 · 2023: 460 · 2022: 525 · 2021: 558 · 2020: 408 · 2019: 255 · 2018: 153 · 2017: 1
- FWCI
- 98.33
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (P30CA006973)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- tumor mutational burden, anti-PD-1 therapy, PD-L1 blockade, immune checkpoint inhibitors, cancer immunotherapy response, predictive biomarkers, cancer types
- MeSH terms
- Antineoplastic Agents, DNA Mutational Analysis, Humans, Models, Genetic, Mutation, Neoplasms, Biomarkers, Tumor, B7-H1 Antigen, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.